SYMBICORT TURBUHALER

Información principal

  • Denominación comercial:
  • SYMBICORT TURBUHALER 320 mcg-9 mcg/ DOSIS POLVO PARA INHALACION ORAL
  • Dosis:
  • 320 mcg-9 mcg/DOSIS (A3)
  • formulario farmacéutico:
  • POLVO PARA INHALACI
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • ASTRAZENECA AB, SUECIA

Documentos

Localización

  • Disponible en:
  • SYMBICORT TURBUHALER 320 mcg-9 mcg/ DOSIS POLVO PARA INHALACION ORAL
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.33.878
  • Fecha de autorización:
  • 01-09-2004
  • última actualización:
  • 03-09-2018

Prospecto: composición, indicaciones, interacción, posología, embarazo, lactancia, reacciones adversas

1-3-2019


Summary of opinion: Trydonis,beclometasone / formoterol / glycopyrronium bromide,  28/02/2019,  Positive

Summary of opinion: Trydonis,beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Summary of opinion: Trydonis,beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Europe - EMA - European Medicines Agency

1-3-2019


Summary of opinion: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),beclometasone / formoterol / glycopyrronium bromide,  28/02/2019,  Positive

Summary of opinion: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Summary of opinion: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Europe - EMA - European Medicines Agency

5-2-2019


Human medicines European public assessment report (EPAR): Bevespi Aerosphere, glycopyrronium / formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 18/12/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Bevespi Aerosphere, glycopyrronium / formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 18/12/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Bevespi Aerosphere, glycopyrronium / formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 18/12/2018, Status: Authorised

Europe - EMA - European Medicines Agency

25-1-2019

Trimbow (Chiesi Farmaceutici S.p.A.)

Trimbow (Chiesi Farmaceutici S.p.A.)

Trimbow (Active substance: beclometasone / formoterol / glycopyrronium bromide) - Centralised - 2-Monthly update - Commission Decision (2019)686 of Fri, 25 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4257/II/02

Europe -DG Health and Food Safety

20-12-2018

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (Active substance: glycopyrronium bromide / formoterol) - New authorisation - Commission Decision (2018)9127 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4245

Europe -DG Health and Food Safety

14-12-2018


Summary of opinion: Trimbow,beclometasone / formoterol / glycopyrronium bromide,  13/12/2018,  Positive

Summary of opinion: Trimbow,beclometasone / formoterol / glycopyrronium bromide, 13/12/2018, Positive

Summary of opinion: Trimbow,beclometasone / formoterol / glycopyrronium bromide, 13/12/2018, Positive

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Europe - EMA - European Medicines Agency

7-8-2018

Duaklir Genuair (AstraZeneca AB)

Duaklir Genuair (AstraZeneca AB)

Duaklir Genuair (Active substance: aclidinium bromide / formoterol fumarate dihydrate) - Centralised - Yearly update - Commission Decision (2018)5419 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

7-8-2018

Brimica Genuair (AstraZeneca AB)

Brimica Genuair (AstraZeneca AB)

Brimica Genuair (Active substance: aclidinium bromide / formoterol fumarate dihydrate) - Centralised - Yearly update - Commission Decision (2018)5420 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

2-5-2018

Trydonis (Chiesi Farmaceutici S.p.A.)

Trydonis (Chiesi Farmaceutici S.p.A.)

Trydonis (Active substance: beclometasone / formoterol / glycopyrronium bromide) - Centralised - Authorisation - Commission Decision (2018)2713 of Wed, 02 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4702

Europe -DG Health and Food Safety

26-4-2018

Riarify (Chiesi Farmaceutici S.p.A.)

Riarify (Chiesi Farmaceutici S.p.A.)

Riarify (Active substance: beclometasone / formoterol / glycopyrronium bromide) - New authorisation - Commission Decision (2018)2581 of Thu, 26 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4836

Europe -DG Health and Food Safety